About US
Contact us
-
WuXi Bio steps up its ADC manufacturing game with a new, dedicated subsidiaryAntibody-drug conjugates are rushing to the fore. Of 11 ADCs on the market today, six have been approved since 2019. That means demand for ADC manufacturing is on the rise—and now answering t2021/5/17
-
Sandoz's Enbrel biosim case turned away at SCOTUS, giving Amgen's blockbuster 8 more years of free reinAfter back-to-back losses in court, Novartis’ generics outfit Sandoz had hoped the U.S. Supreme Court would take up itslong shot biosimilarscase against Enbrel maker Amgen. But now that effort has fa2021/5/17
-
Seagen's set for major growth, but Padcev sales estimates are a 'tall order': analystSeagen is one of the industry’s antibody-drug conjugate powerhouses. Its growth hinges on bladder cancer drug Padcev and small-molecule breast cancer med Tukysa, which carry blockbuster sales estimat2021/5/14
-
Sanofi, touting new data, sees 'best-in-class' case for Dupixent in pediatric asthmaSanofi's Dupixent is already off and running in several key markets—including eczema and adult asthma—and churning up blockbuster sales. Now, with a potential FDA approval in childhood asthma forthco2021/5/14
-
J&J, Bayer pad case for Xarelto in post-surgery artery disease patientsWith an approvalfiling alreadyon the FDA’s docket, Bayer and Johnson & Johnson are padding their case for launching legacy blood thinner Xarelto in arterydisease patients after surgery. In long-t2021/5/12
-
Regeneron's Evkeeza aces triglyceride control, but only in certain patientsRegeneron’s new med Evkeeza already sports an approval in the ultra-rare disease homozygous familial hypercholesterolemia, which is associated with extreme levels of cholesterol. But thanks to compet2021/5/12
-
Regeneron's Eylea beats out the competition in the U.S. as patient demand picks back upIn their battle for a larger piece of themacular degeneration pie, Regeneron's Eylea is edging outRoche's Lucentis in the key U.S. market. With sales of $1.35 billion in the first quarter, a 15% incr2021/5/10
-
An Alzheimer's med for $2,500? Watchdog blasts Biogen's aducanumab data, suggests low priceConflicting clinical results from Biogen and Eisai’s closely watched Alzheimer’s disease candidate aducanumab have already fueled plenty of controversies. Now aU.S. drug pricing watchdog has used tha2021/5/10
-
Moderna CEO says he's not losing any sleep over Biden's support for COVID-19 vaccine waiverModerna shares plummeted overnight alongside fellow COVID-19drugmakers after the Biden administration came out in favor of temporarily waiving intellectual property rights for their vaccines. But toM2021/5/8
-
Catalent snares yet another Belgian CDMO to boost fast-growing cell and gene therapy campusSince purchasingcell and gene therapy CDMO MaSTherCell early last year, Catalent has been on an M&A tear in Belgium. With yet another deal, it’sbringing another local manufacturer—and a newfactor2021/5/8